TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy Before Surgery Compared With Chemotherapy Plus Radiation After Surgery in Treating Patients With Rectal Cancer That Can Be Surgically Removed

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed adenocarcinoma of the rectum (defined as lower edge of tumor within 15 cm of anal verge)~* Tumor considered potentially operable~* No evidence of metastases indicated by liver ultrasound or CT scan; chest x-ray; or renal, liver, and bone profiles~PATIENT CHARACTERISTICS:~Age:~* 75 and under~Performance status:~* Not specified~Life expectancy:~* Not specified~Hematopoietic:~* Not specified~Hepatic:~* Not specified~Renal:~* Not specified~Cardiovascular:~* No uncontrolled heart failure or angina~Other:~* No other concurrent uncontrolled medical illness (e.g., infection)~* No other prior or concurrent malignancy likely to interfere with the protocol treatments or comparisons~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* Not specified~Endocrine therapy~* Not specified~Radiotherapy~* Not specified~Surgery~* Not specified

- Gender: ALL
- Minimum Age: None
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Total Dose Infusion of Ferumoxytol(1020mg) in 15 Minutes for Iron Deficiency Anemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Iron deficiency anemia intolerant of or failure to respond to oral iron or condition where oral iron is known to be ineffective or harmful.~* Subject must be able to be contacted at 24-48 hours after dose and come for followup at four weeks.~* Subject must be capable of understanding informed consent~* No other form of iron may be taken within four weeks of consent or for four weeks after treatment~Exclusion Criteria:~* History of hypersensitivity to ferumoxytol.~* Imminent dialysis.~* Anemia due to other etiology.~* Parenteral iron within 4 weeks of consent.~* Pregnancy.~* Erythropoiesis stimulating agent within 30 days of consent.~* Other illness that would interfere with participation or understanding of trial.~* Major surgery planned within four weeks of consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- ferumoxytol (Type: OTHER): IV administration of 1020 mg of ferumoxytol in 15 minutes

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Secondary Prophylaxis of Hepatic Encephalopathy With a Probiotic Preparation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed as having cirrhosis of liver at the Inpatient/Outpatient Liver Clinic of Department of Hepatology, PGIMER, Chandigarh, will be candidates for enrollment.~* The diagnosis of cirrhosis of liver will be based on clinical, biochemical, and ultrasonographical or liver histological data.~Exclusion Criteria:~* Alcohol intake during the past 6 weeks~* Hepatocellular carcinoma~* Previous transjugular intrahepatic portosystemic shunt or shunt surgery~* Significant comorbid illness such as heart, respiratory, or renal failure~* Any neurologic diseases such as Alzheimer's disease, Parkinson's disease, and nonhepatic metabolic encephalopathies.~* Patients on psychoactive drugs, such as antidepressants or sedatives~* Those who restart alcohol consumption during follow-up will also be excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- VSL#3 (Type: EXPERIMENTAL): VSL#3® is made up of 4 strains of Lactobacilli (L. paracasei, L. plantarum, L. acidophilus and L. delbrueckii subsp. bulgaricus), 3 strains of Bifidobacteria (B. longum, B. infantis, B. breve) and 1 strain of Streptococcus thermophilus.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo sachets contain corn starch

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Has at least a 1-year history of migraine with or without aura~* Age of the patient at the time of migraine onset \< 50 years~* History of 4 to 14 migraine days (migraine/probable migraine headache days) per month on average in the 3 months prior to Visit 1 in the Investigator's judgment~* Demonstrated compliance with e-diary~Exclusion Criteria:~* Has a history of migraine accompanied by diplopia or decreased level of consciousness and retinal migraine~* Has a current diagnosis of chronic migraine, new persistent daily headache, trigeminal autonomic cephalgia (eg, cluster headache), or painful cranial neuropathy~* Difficulty distinguishing migraine headache from other headaches~* Has a history of malignancy in the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer~* Has a history of gastric or small intestinal surgery, or has a disease that causes malabsorption~* Has a history of hepatitis within previous 6 months~* Usage of opioids or barbiturates \> 2 days/month, triptans or ergots ≥ 10 days/month, or simple analgesics (eg, aspirin, non-steroidal anti-inflammatory drugs \[NSAIDs\], acetaminophen) ≥ 15 days/month in the 3 months prior to Visit 1~* Pregnant or nursing females

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo-matching atogepant capsule orally twice daily in the morning and in the evening for 12 weeks.
- Atogepant 10 mg QD (Type: EXPERIMENTAL): Atogepant 10 mg capsule orally once daily (QD) in the morning and one placebo-matching atogepant capsule orally once daily in the evening for 12 weeks.
- Atogepant 30 mg QD (Type: EXPERIMENTAL): Atogepant 30 mg capsule orally once daily in the morning and one placebo-matching atogepant capsule orally once daily in the evening for 12 weeks.
- Atogepant 30 mg BID (Type: EXPERIMENTAL): Atogepant 30 mg capsule orally twice daily (BID); 1 capsule in the morning and 1 capsule in the evening for 12 weeks.
- Atogepant 60 mg QD (Type: EXPERIMENTAL): Atogepant 60 mg capsule orally once daily in the morning and one placebo-matching atogepant capsule orally in the evening for 12 weeks.
- Atogepant 60 mg BID (Type: EXPERIMENTAL): Atogepant 60 mg capsule orally twice daily; 1 capsule in the morning and 1 capsule in the evening for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vitamin D3 Supplementation for Heart Failure Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* NYHA Heart Failure Class II or II, stable~* Vitamin D deficiency (32 ng/ml or less)~* No recent medication changes for 3 months~* Females of childbearing age must use effective contraceptive if they are sexually active~Exclusion Criteria:~* Hypercalcemia~* Nephrolithiases~* Sarcoidosis~* Acute cardiac insufficiency~* Pregnancy~* Breastfeeding~* Any clinically unstable medical condition~* Supplements of greater than or equal to 1000 units of vitamin D per day

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vitamin D3 (cholecalciferol) (Type: ACTIVE_COMPARATOR): 10,000 International Units of vitamin D3 will be given daily for 6 months in vitamin D deficient heart failure patients.
- Sugar Pill (Type: PLACEBO_COMPARATOR): Patients will be given an placebo that is identical in appearance to the active comparator. It will be given as 2 gelcaps per day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mifepristone for Labor Induction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Pregnant patients between ages 18 to 45 years~2. Singleton, live gestation~3. Nulliparous~4. Gestational age between 37 weeks 0 days - 42 weeks 0 days~5. Fetus in cephalic presentation~6. Patients admitted for labor induction~7. Patients who are not in labor with intact membranes~8. Patients with no contraindication for vaginal delivery (placenta previa, vasa previa, active genital herpes)~9. Patients with no contraindications for mifepristone (chronic adrenal failure, concurrent long-term corticosteroid therapy, history of allergy to mifepristone, or other prostaglandins, hemorrhagic disorders or concurrent anticoagulant therapy, inherited porphyria, or an intrauterine device (IUD) in place)~10. Patients with a Bishop score \<6 at time of randomization~11. Transcervical balloon in place \<3 hours prior to the time of randomization without prior cervical preparation~Exclusion Criteria:~1. Significant cardiac, renal, or hepatic maternal comorbidities, severe gestational hypertension or preeclampsia with severe features~2. Pregnancies complicated by major fetal anomalies~3. Patients with a uterine scar~4. Pregnancies complicated by fetal growth restriction (Estimated fetal weight \<10%)~5. Pregnancies complicated by oligohydramnios~6. Fetuses with an estimated fetal weight \>4500 gm by recent ultrasound or Leopold's exam on admission~7. Patients with class 3 obesity (BMI \>40)~8. Fetuses with a persistent category 2 or 3 fetal heart tracing at labor induction admission~9. Vaginal bleeding at the time of randomization~10. Any indication for scheduled cesarean delivery~11. Hypersensitivity to oxytocin~12. Uterine contractions equal to or greater than 5 in 10 minutes for sustained 30 minutes~13. Hypersensitivity to prostaglandins

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Mifepristone (Type: ACTIVE_COMPARATOR): Participants will be given mifepristone with insertion of the cervical Cook balloon for labor induction
- Misoprostol (Type: ACTIVE_COMPARATOR): Participants will be given misoprostol with insertion of the cervical Cook balloon for labor induction

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dual Therapy With Raltegravir and Darunavir/Ritonavir in HIV Infected Patients.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Documented HIV infection~* Naïve to Raltegravir.~* CD4 cell count above 200 cell/mm3.~* No history of failure to PI containing regimens.~* No evidence of PI mutations (IAS-mutation list) by genotype test.~* Failing to a NRTI based regimen.~* The treating physician decides a NRTI sparing regimen which includes DRV/r 800/100 mg QD plus Raltegravir 400 mg BID.~* Signed informed consent form~* In opinion of the investigator, the patient should be considered clinically stable and could follow regular visits as scheduled per protocol.~Exclusion Criteria:~* Patients receiving drugs considered contraindicated to Raltegravir and DRV/r. Contraindicated drugs are: rifampin, fenitoin, phenobarbital in the case of raltegravir. Pravastatin, astemizole, sildenafil, are contraindicated in combination with DRV/r.~* Pregnancy~* Documented PI mutations

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Single arm with dual therapy (Type: None): Dual therapy RAL 400 mg bid + DRV/r 800/100 mg QD

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sitagliptin Versus Insulin Dose Increase in Type 2 Diabetes on Insulin Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes~* HbA1c ≥ 7%~* Age ≥ 18~* Insulin treatment with or without oral antidiabetic medication~Exclusion Criteria:~* Contraindication to sitagliptin~* Pregnant or breast feeding women~* Type 1 diabetes, gestational diabetes, or diabetes with secondary cause~* Chronic hepatitis B or C (except healthy carrier of HBV), liver disease (AST/ALT \> 3-fold the upper limit of normal)~* Renal failure (Cr \> 2.0)~* Cancer within 5 years~* Not appropriate for oral antidiabetic agent~* Medication which affect glycemic control~* Disease which affect efficacy and safety of drugs~* Other clinical trial within 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- sitagliptin (Type: EXPERIMENTAL): None
- insulin dose increase (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 5-Alpha Reductase and Anabolic Effects of Testosterone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 60 years males~* Primary care at the Malcolm Randall VA Medical Center in Gainesville, Florida.~* Consenting subjects who have a morning (between 6:00 AM and 10:00 AM) serum total testosterone 300 ng/dL or bioavailable testosterone concentration 70 ng/dL and no exclusion criteria will be randomized to receive either testosterone or placebo.~Exclusion Criteria:~* Subjects with cognitive impairment will be identified by the Mini-Cog test and excluded. The Mini-Cog has high sensitivity and specificity for cognitive impairment, and is not affected by level of education.~* We will also exclude subjects with receptive aphasia, or a contraindication to testosterone replacement (i.e., history of or active prostate or breast cancer, severe benign prostatic hyperplasia as assessed by elevated American Urologic Association Symptom Index (AUASI) score \> 25), congestive heart failure (Class 3 or 4), sleep apnea syndrome, polycythemia (Hct \> 55%), or prostate specific antigen (PSA) \> 2.6 ng/mL) will be excluded.~* Obese subjects (BMI \> 35) will also be excluded.~* Subjects currently receiving testosterone supplementation or subjects who have an allergy to testosterone will also be excluded.~* Subjects previously receiving testosterone replacement therapy must be off such medication for at least four weeks.

- Gender: MALE
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): testosterone enanthate
- Arm 2 (Type: EXPERIMENTAL): finasteride
- Arm 3 (Type: EXPERIMENTAL): testosterone enanthate + finasteride
- Arm 4 (Type: PLACEBO_COMPARATOR): placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study to Test the Efficacy and Safety of ACYC to Treat Moderate to Severe Acne

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Male or female between the ages of 12 and 40 (inclusive)~* Written and verbal informed consent must be obtained.~* Subjects less than 18 years of age must sign an assent for the study and a parent or a legal guardian must sign the informed consent~* Subject must have moderate to severe acne at the baseline visit~* Women of childbearing potential must be willing to practice effective contraception for the duration of the study~Key Exclusion Criteria:~* Use of an investigational drug or device within 30 days of enrollment or participation in a research study concurrent with this study~* Dermatological conditions on the face that could interfere with clinical evaluations

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- ACYC (Type: ACTIVE_COMPARATOR): ACYC active, topically applied to the face for 12 weeks
- ACYC vehicle (Type: PLACEBO_COMPARATOR): ACYC vehicle (placebo), topically applied to the face for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity Study of a Dengue Virus DNA Vaccine

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Available to participate for the duration of the study (approximately 12 months)~* Completion and review of knowledge assement quiz~Exclusion Criteria:~* Pregnant (by history or as ascertained by pregnancy test) or lactating female~* Female who intends to become pregnant during the study~* Plan to have elective surgery during the study period~* HIV infection~* Known immunodeficiency or currently receiving immunosuppressive therapy (inhaled and topical steroids are allowed)~* History of splenectomy~* Administration of a vaccine not foreseen by the study protocol during the period starting 30 days before each dose of vaccine and ending 30 days after vaccination~* Evidence of active (acute or chronic) hepatitis B or C infection~* Autoimmune diseaseor subjects who describe a first-degree relative with clearly documented autoimmune disease~* Acute or chronic, clinically significant cardiac, pulmonary, hepatic, or renal abnormality, as determined by physical examination or basic laboratory screening~* Clinical or laboratory evidence of significant anemia~* History of flavivirus infection or previous receipt of flavivirus vaccine~* Positive serology for flaviviruses (all four dengue virus serotypes, Japanese encephalitis, Yellow fever virus, and West Nile virus), HIV-1, Hepatitis B surface antigen, or anti-hepatitis C virus antibodies prior to enrollment~* Use of any investigational or non-registered drug or vaccine other than the study vaccine within 60 days preceding the first dose of study vaccine, or planned use during the study period.~* Previous history of allergic or anaphylactic reaction to any vaccine~* Planned travel to areas with endemic dengue during the study period~* Any other significant finding which, in the opinion of the investigator, would increase the risk of having an adverse outcome from participating in this protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- 1.0 mg of D1ME100 vaccine (Type: EXPERIMENTAL): 1.0 mg dose of DME100 vaccine delivered by Biojector IM injections at 0, 1 and 5 months
- 5.0 mg of D1ME100 vaccine (Type: EXPERIMENTAL): 5.0 mg dose of DME100 vaccine delivered by Biojector IM injections at 0, 1 and 5 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children, Adolescents and Adults (3 to 64 Years)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Children, adolescents, and adults 3 to 64 years of age in good health as determined by medical history, physical assessment and clinical judgement of the investigator and without influenza within the past 6 months.~Exclusion Criteria:~* History of serious disease.~* History of serious reaction following administration of vaccine or hypersensitivity to vaccine components.~* Known or suspected impairment/alteration of immune function.~* Receipt or planned receipt of seasonal trivalent influenza vaccine within 1 week before or after each study vaccination.~For additional entry criteria, please refer to protocol.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- 2x7.5adj (Type: EXPERIMENTAL): Two doses of MF59 adjuvanted (adj) A/H1N1
- 7.5adj_1_8 (Type: EXPERIMENTAL): MF59 adjuvanted (adj) A/H1N1 on days 1 and 8
- 7.5adj_1_22 (Type: EXPERIMENTAL): MF59 adjuvanted (adj) A/H1N1 on study days 1 and 22
- 15_1_22 (Type: EXPERIMENTAL): A/H1N1 on study days 1 and 22
- 2x15_1_22 (Type: EXPERIMENTAL): Two doses of A/H1N1 (one in each arm) on study days 1 and 22

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety Study on IdeS in Healthy Volounteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ability to understand and sign informed consent~* BMI 19-30~Exclusion Criteria:~* Clinically significant disease~* Positive HIV, hepatistis B or C~  * Drug abuse~* Smoking~* Use of medication except paracetamol

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- IdeS (Type: EXPERIMENTAL): Intravenous infusion
- PBS Buffer (Type: PLACEBO_COMPARATOR): Intravenous infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete